Preliminary test results show that Eli Lilly’s (LLY) daily weight-loss pill, called Orforglipron, is as effective as the company’s injectable GLP-1 drug Zepbound.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The weight-loss pill from Eli Lilly is also equally good at lowering blood sugar levels in people with diabetes, according to new data from a Phase 3 clinical trial. The results were announced at the annual meeting of the American Diabetes Association and the findings published in the prestigious New England Journal of Medicine.
Pharmaceutical giant Eli Lilly currently makes the blockbuster drug Mounjaro for Type 2 diabetes and Zepbound for weight management. Like rival Novo Nordisk’s (NVO) Ozempic and Wegovy, both of Eli Lilly’s drugs are injected by people on a weekly basis. However, a weight-loss pill is widely viewed as a potential gamechanger given many people’s fear of needles and difficulty injecting themselves.
Race for the Pill
Eli Lilly, Novo Nordisk, and other pharmaceutical companies are racing to bring a weight-loss pill to market. Eli Lilly’s Orforglipron pill is currently in late stage clinical trials and could be approved by the U.S. Food and Drug Administration (FDA) in 2026, though an exact date is not yet known.
So far, preliminary data on Eli Lilly’s pill to help manage obesity is showing promising results. “What we see is that the efficacy, safety, and tolerability are really consistent with the very best injectable (medications),” said Kenneth Custer, President of Cariometabolic Health at Eli Lilly, in a news release concerning the company’s experimental pill. “We think this is a big deal.”
Is LLY Stock a Buy?
The stock of Eli Lilly has a consensus Strong Buy recommendation among 19 Wall Street analysts. That rating is based on 16 Buy, two Hold, and one Sell recommendations issued in the last 12 months. The average LLY price target of $999.57 implies 28.83% upside from current levels.
